Corvidane is developing Corvida™  to treat TWO formidable diseases.

Corvidane uses a novel approach to treat metabolic and inflammatory diseases.

Corvida(TM) for Atherosclerosis - In development to be a Best-in-Class, orally administered adjunct to lipid regulating therapies (Statins/PCSK9) that targets atherosclerotic plaques, the major factor in Heart Attacks and Stroke.

Corvida(TM) for MASH - In development to be a Best-in-Class, orally administered drug to treat MASH, which is the leading cause of liver transplants in the United States.

Corvidane

Org chart

Teams

Offices

Corvidane

Org chart

Teams

Offices

Related companies